ArticleScientific reports2025
Genomic evidence of varicella-zoster virus among Mpox-suspected cases in Ethiopia during the 2022 Mpox multi-country outbreak.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cocirculation of Human Monkeypox Virus Clade 1b with Varicella Zoster Virus, Uganda.Emerging infectious diseases · 2026Article
- The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop.BMC proceedings · 2026Article
- Targeted metagenomics reveals hidden chickenpox epidemic amid Mpox surveillance in Uganda.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chickenpox is a highly contagious viral infection caused by varicella-zoster virus (VZV) whose clinical manifestations mimic mpox posing challenges for diagnosis without laboratory confirmation. Here, we investigated VZV among the mpox-suspected cases, May to October 2022, in Ethiopia. Samples were collected from 202 mpox-suspected cases in 11 of Ethiopia's 14 regions and screened for mpox virus by real-time polymerase chain reaction (RT-PCR). Then, differential testing of other selected orthopoxviruses, VZV and herpes simplex virus (HSV) were conducted for 133 randomly selected samples. Whole-genome sequencing (WGS) and downstream analysis was performed on 8 VZV-positive samples. Descriptive statistics were used to summarize epidemiological and clinical data. All the 202 enrolled cases tested negative for mpox. Of these, 133 samples were tested for VZV, and 107 (80.5%, 95% CI: 72.9% - 86.3%) turned positive but remained negative for HSV and other tested orthopoxviruses. At least one VZV-positive case was reported in each region sampled. Half (49.6%) of the cases were hospitalized, with no fatalities. The sequences were clustered primarily in Clade 5 (62.5%, 5) followed by Clade 3 (25.0%, 2) and Clade 1 (12.5%, 1). This investigation confirmed VZV as the predominant causative agent among mpox-suspected cases. To our knowledge, this represents the first clade-level genomic characterization of VZV from Ethiopia, revealing circulation of multiple clades among samples collected during May to October 2022. The findings highlight the need to strengthen differential diagnostic capacities including multiplex testing, and building genomic surveillance capacities for epidemic intelligence and outbreak response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.